Servier will participate in the 33rd edition of the ECNP (European College of Neuropsycho Pharmacology), the largest European congress dedicated to innovation in neuropsychiatric diseases, from September 12 to 15. More than 4 000 participants are expected to attend this virtual 2020 edition.
Each year, ECNP brings together psychiatrists, neuroscientists, and neurologists from around the world to exchange on the latest research results, new treatments for brain disorders, and new technologies in the field of neuroscience.
Servier, partner of the event, will provide materials with information on its activities via its digital booth for healthcare professionals. The Group’s Medical Affairs will organize a scientific session with a pedagogical aim on generalized anxiety disorders and the treatment of depression. Recent data in psychiatry and autism will also be presented through posters. The neuropsychiatry franchise will present, among other things, two brochures developed in collaboration with GAMIAN-Europe to support patients suffering from depression.
Did you know?
Servier has been involved in neuropsychiatry for several decades and makes therapeutic solutions available to patients suffering from depression. The research and development teams work on both neurodegenerative and neurodevelopmental disorders such as autism, to provide innovative therapeutic solutions.
Servier is contributing to the development of a therapy adapted to children and teenagers with autism spectrum disorders that can be integrated into the multidisciplinary management of these disorders. It aims to improve the social interactions and communication of these individuals as well as their restrictive and repetitive behaviors.